{"entity":{"type":"insider","cik":"0001781982","url":"/insider/0001781982","json_url":"/insider/0001781982.json","name":"Ellison Mark Jason Heath","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":3,"n_filings":3,"first":"2023-01-05","last":"2023-01-31","span_basis":"filed_date"},"name_variants":[{"name":"Ellison Mark Jason Heath","source":"filing","n_filings":3,"first_seen":"2023-01-05","last_seen":"2023-01-31"}],"transactions":[{"id":8762753,"accession":"0001385508-23-000033","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001385508-23-000033","line_url":"/filing/0001385508-23-000033#line-1","is_derivative":false,"issuer_cik":"0001385508","issuer_name":"OPIANT PHARMACEUTICALS, INC.","issuer_ticker":"OPNT","issuer_name_source":null,"issuer_url":"/issuer/0001385508","owner_cik":"0001781982","owner_name":"Ellison Mark Jason Heath","owner_display_name":"Ellison Mark Jason Heath","owner_url":"/insider/0001781982","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":610.0,"shares_display":"610","price_per_share":20.26,"price_display":"20.26","price_state":"stated","total_value":12358.6,"total_display":"12,358.60","total_whole":"12,359","shares_owned_after":18751.0,"shares_owned_after_display":"18,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-27","filed_date":"2023-01-31","scope":"insider"},{"id":8684068,"accession":"0001385508-23-000022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001385508-23-000022","line_url":"/filing/0001385508-23-000022#line-1","is_derivative":false,"issuer_cik":"0001385508","issuer_name":"OPIANT PHARMACEUTICALS, INC.","issuer_ticker":"OPNT","issuer_name_source":null,"issuer_url":"/issuer/0001385508","owner_cik":"0001781982","owner_name":"Ellison Mark Jason Heath","owner_display_name":"Ellison Mark Jason Heath","owner_url":"/insider/0001781982","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":469.0,"shares_display":"469","price_per_share":20.2,"price_display":"20.20","price_state":"stated","total_value":9473.8,"total_display":"9,473.80","total_whole":"9,474","shares_owned_after":19361.0,"shares_owned_after_display":"19,361","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-09","filed_date":"2023-01-09","scope":"insider"},{"id":8415712,"accession":"0001385508-23-000013","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001385508-23-000013","line_url":"/filing/0001385508-23-000013#line-1","is_derivative":false,"issuer_cik":"0001385508","issuer_name":"OPIANT PHARMACEUTICALS, INC.","issuer_ticker":"OPNT","issuer_name_source":null,"issuer_url":"/issuer/0001385508","owner_cik":"0001781982","owner_name":"Ellison Mark Jason Heath","owner_display_name":"Ellison Mark Jason Heath","owner_url":"/insider/0001781982","role":"Officer (Chief Development Officer)","role_mark":"O","role_mark_label":"Officer (Chief Development Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1806.0,"shares_display":"1,806","price_per_share":20.2,"price_display":"20.20","price_state":"stated","total_value":36481.2,"total_display":"36,481.20","total_whole":"36,481","shares_owned_after":19830.0,"shares_owned_after_display":"19,830","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-05","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":3,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":3,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":3},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001385508","name":"OPIANT PHARMACEUTICALS, INC.","url":"/issuer/0001385508","role":"Officer (Chief Development Officer)","n_filings":3,"first_seen":"2023-01-05","last_seen":"2023-01-31"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001781982","retrieved_at":"2026-08-22T04:57:07+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}